Treatment of HIV-associated Burkitt Lymphoma in the presence of severe hepatic dysfunction.
Chen
Robert
R
Hematologic Malignancies and Blood and Marrow Transplant Program, Division of Medical Oncology, University of Colorado Cancer Center, USA. robert.chen@uchsc.edu
Abbott
Brian L
BL
Myint
Han
H
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002051:Burkitt Lymphoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D015251:Epirubicin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone